Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 6

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 6
---
 the same general meeting, our shareholders approved the cancellation
of admission of our Ordinary Shares on AIM and this cancellation became effective on April 26, 2023.

Concurrently with the reverse split,
and in order to continue meeting The NASDAQ Stock Market LLC’s, or NASDAQ, minimum 500,000 publicly held shares requirement pursuant
to Rule 5550(a)(4), on March 27, 2023 we effected a ratio change in the number of Ordinary Shares represented by the Depositary Shares
from 25 Ordinary Shares per Depositary Share to five Ordinary Shares per Depositary Share.

On June 14, 2023, we held our annual
general meeting of shareholders, or June AGM, and our shareholders passed resolutions, among other procedural items, to approve the allotment
of, and disapplication of pre-emption rights in respect of, up to 7.0 billion Ordinary Shares, or Shareholder Approval. On June 14, 2023,
we also held a separate general meeting of shareholders, or June GM, and our shareholders passed resolutions to (x)(i) re-designate our
deferred shares into A deferred shares, or the Re-Designation, and (ii) subdivide our Ordinary Shares of £0.02 nominal value each
into one ordinary share of £0.001 nominal value and 19 B Deferred Shares of £0.001 nominal value each, each the Subdivision,
and (y) adopt new articles of association, or the Articles of Association, which made consequential amendments to the existing Articles
of Association of the Company to reflect the Re-Designation and the Subdivision, together with certain other changes to reflect that
the Ordinary Shares were no longer admitted to trading on AIM. As is standard for deferred shares, each B deferred share has very limited
rights and is effectively valueless. The B deferred shares have the rights and restrictions as set out in the Articles of Association
and do not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend
or other distribution.

On July 5, 2023, and in an effort to bring
our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected a ratio change in
the number of Ordinary Shares represented by our Depositary Shares from five Ordinary Shares per Depositary Share to 400 Ordinary Shares
per Depositary Share. No fractional Depositary Shares were issued.

On October